Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 78 publications
More options, more questions in the management of early relapsed and/or refractory multiple myeloma.
More options, more questions in the management of early relapsed and/or refractory multiple myeloma.
Journal: Nature reviews. Clinical oncology
Published: July 31, 2026
Robust CD4+ CAR T cell expansion is associated with non-ICANS neurotoxicities after ciltacabtagene autoleucel in patients with multiple myeloma.
Journal: Science translational medicine
Published: July 29, 2026
Effectiveness of daratumumab plus bortezomib, lenalidomide, and dexamethasone (DVRd) versus VRd for transplant-eligible newly diagnosed multiple myeloma.
Journal: Future oncology (London, England)
Published: July 14, 2026
Practical Management of Bispecific Antibodies in Multiple Myeloma.
Journal: JCO oncology practice
Published: June 17, 2026
Review of the first on-body injector (OBI) for the subcutaneous delivery of an oncology drug: isatuximab in multiple myeloma.
Journal: Expert opinion on drug delivery
Published: April 13, 2026
Real-World Evaluation of Talquetamab for the Treatment of Relapsed/Refractory Multiple Myeloma (RRMM): An International Myeloma Working Group Immunotherapy Registry Real-World Analysis.
Journal: American journal of hematology
Published: March 04, 2026
A pilot trial evaluating lenalidomide and oral azacitidine with radiotherapy for patients with newly diagnosed and relapsed plasmacytoma.
Journal: Haematologica
Published: February 05, 2026
Low Dose Tocilizumab for Mitigation of Cytokine Release Syndrome With T-Cell Engaging Bispecific Antibodies.
Journal: Clinical lymphoma, myeloma & leukemia
Published: January 30, 2026
Robust CD4+ CAR T cell Expansion Is Associated with Non-ICANS Neurotoxicities Following Ciltacabtagene Autoleucel.
Journal: medRxiv : the preprint server for health sciences
Published: November 24, 2025
Last Updated: 09/26/2026